npcnow.org
CER Daily Newsfeed® | National Pharmaceutical Council
http://www.npcnow.org/cernewsfeed
Skip to main content. Standards for Real-World Evidence. Impact of Benefit Restrictions. VBID: Value-Based Insurance Design. Spending Wisely on Health. Paying Differently for Health. Disease Management and Medicaid Health Outcomes Management. Medicaid Plan Pharmaceutical Resources. Medicare Part D Drug Benefit. News from Monday, April 10, 2017. Enbrel's First Outcomes Contract Is With Harvard Pilgrim; Others May Follow. 4/7, Cathy Kelly,. Study: New Diabetes Drug Class Reduces Heart Deaths. Reports ....
npcnow.com
Newsroom | National Pharmaceutical Council
http://www.npcnow.com/newsroom
Understanding how treatments work in the real world is important. Read more. It’s important to assess value through a patient-focused lens. Read more. When Is Evidence "Fit for Purpose"? Spending Patterns for High Resource Patients Read more. Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed. AHA: Drug Makers Should Submit Comparative Effectiveness Data As Part Of FDA Approvals (10/12, Erin Durkin, InsideHealthPolicy.com). Treatment for c...
npcnow.net
News from Thursday, October 13, 2016 | National Pharmaceutical Council
http://www.npcnow.net/cernewsfeed
Understanding how treatments work in the real world is important. Read more. It’s important to assess value through a patient-focused lens. Read more. When Is Evidence "Fit for Purpose"? Spending Patterns for High Resource Patients Read more. News from Thursday, October 13, 2016. Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed. Baricitinib for Rheumatoid Arthritis More Effective Than Methotrexate (10/13, Lauren Santye, AJPB Live). Monda...
npcnow.net
Newsroom | National Pharmaceutical Council
http://www.npcnow.net/newsroom
Understanding how treatments work in the real world is important. Read more. It’s important to assess value through a patient-focused lens. Read more. When Is Evidence "Fit for Purpose"? Spending Patterns for High Resource Patients Read more. Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed. AHA: Drug Makers Should Submit Comparative Effectiveness Data As Part Of FDA Approvals (10/12, Erin Durkin, InsideHealthPolicy.com). Treatment for c...
invivo.pharmamedtechbi.com
Speak Up! :: In Vivo
https://invivo.pharmamedtechbi.com/IV004972/In-Vivo-Needs-You
This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy. In Vivo is part of the Business Intelligence Division of Informa PLC. This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call 44 (0) 20 3377 3183. Your opinion matters to us. Please complete our fast, no-strings survey to tell us what you think about In Vivo. Thanks, weve se...
invivo.pharmamedtechbi.com
Author Detail :: In Vivo
https://invivo.pharmamedtechbi.com/authors/sarah-rickwood
This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy. In Vivo is part of the Business Intelligence Division of Informa PLC. This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call 44 (0) 20 3377 3183. Set Alert for Articles By Sarah Rickwood. Are you sure you'd like to remove this alert? Yes, I'm Sure. Latest From Sarah Rickwood.
medtech.pharmamedtechbi.com
Author Detail :: Medtech Insight
https://medtech.pharmamedtechbi.com/authors/beth-detuzzi
This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy. Medtech Insight is part of the Business Intelligence Division of Informa PLC. This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call 44 (0) 20 3377 3183. Warning Letter Roundup and Recap. Data Tracker: Venture Funding. Data Tracker: US FDA Warning Letters. Yes, I'm Sure.
rose.pharmamedtechbi.com
Author Detail :: Rose Sheet
https://rose.pharmamedtechbi.com/authors/derrick-gingery
This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy. Rose Sheet is part of the Business Intelligence Division of Informa PLC. This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call 44 (0) 20 3377 3183. When he's not following FDA, Derrick is keeping close tabs on Indiana Hoosiers basketball. Yes, I'm Sure. President wants sub...
rose.pharmamedtechbi.com
Advertising :: Rose Sheet
https://rose.pharmamedtechbi.com/advertising
This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy. Rose Sheet is part of the Business Intelligence Division of Informa PLC. This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call 44 (0) 20 3377 3183. Access the Most Senior Level Decision-Makers at Health Care Products Companies. Independent analysis and insight to drive fut...
rose.pharmamedtechbi.com
Author Detail :: Rose Sheet
https://rose.pharmamedtechbi.com/authors/malcolm-spicer
This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy. Rose Sheet is part of the Business Intelligence Division of Informa PLC. This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call 44 (0) 20 3377 3183. Senior Editor, Consumer Health. Advertising, Marketing and Sales. Set Alert for Articles By Malcolm Spicer. Yes, I'm Sure.
SOCIAL ENGAGEMENT